Resistance mechanisms to immune checkpoint inhibitors: updated insights
Open accessThe DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
The last decade has witnessed unprecedented succusses with the use of immune checkpoint inhibitors in treating cancer. Nevertheless, the proportion of patients who respond favorably to the treatment remained rather modest, partially due to treatment resistance. This has fueled a wave of research into potential mechanisms of resistance to immune checkpoint inhibitors which can be classified into primary resistance or acquired resistance after an initial response. In the current review, we summarize what is known so far about the mechanisms of resistance in terms of being tumor-intrinsic or tumor-extrinsic taking into account the multimodal crosstalk between the tumor, immune system compartment and other host-related factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · cited 1×
“Tumors with MSI-high were associated with higher TMB and neoantigen load, stronger local and systemic immune responses and higher sensitivity to immunotherapeutic agents, compared to microsatellite stable tumors (MSS) [50–52].”
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“The objective response rate (ORR) can range from 40–70% in some malignancies such as melanoma, Hodgkin’s lymphoma and microsatellite instability (MSI)-high tumors, while it can be as low as 10–25% in most other cancers [12, 18, 19].”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · cited 1×
“…tumors with high TMB and neoantigen load such as melanoma, head and neck squamous cell carcinoma (HNSCC) and non-small cell lung carcinoma (NSCLC) are known to be more responsive to ICIs, compared to poorly immunogenic tumors with low TMB such as prostate and pancreatic cancers [36, 39, 40].”
Structural absorption by barbule microstructures of super black bird of paradise feathers
McCoy, D. E., Feo, T., Harvey, T. A., & Prum, R. O. (2018) · Nature Communications · doi:10.1038/s41467-017-02088-w · Cited by 7,424
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 3×
“The anti-tumor immune response is a complex process composed of a series of steps that can be linked in the CI Cycle [23, 24].”
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 2×
“Furthermore, studies have demonstrated that MSI-high tumors with inactivating mutations in β2M can still respond to ICIs, suggesting that neoantigen-rich tumors are capable to present their antigens independently from β2M protein [52, 119].”
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“…clinical efficacy of ICIs has been positively correlated with T cell-derived biomarkers including the pre-exist-ence of CD8 + cytotoxic T cells at the invasive tumor margin and within the tumor, close proximity of PD-1 + cells and PD-L1 + cells in addition to the clonal T cell repertoire [46, 144].”
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“It has been suggested that the continuous interaction between cancerous cells and immune system prompts the selection of resistant tumor subclones that lack neoantigens expression [42, 43].”
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · cited 3×
“For example, the immune-related adverse events post treatment and antibiotic consumption could disrupt the gut microbiome and account for secondary resistance to ICIs [225, 230].”
Metadata
- Authors
- Alsaafeen, B. H., Ali, B. R., & Elkord, E.
- Venue
- Molecular Cancer
- Published
- 2025-01-15
- Volume
- 24
- Issue
- 1
- Pages
- 20-20
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W4406405667
- Cited by
- 191
- References
- 85
- FWCI
- 69.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resistance mechanisms to immune checkpoint inhibitors: updated insights. https://app.cochat.ai/papers/10.1186/s12943-024-02212-7
- The paper
- Alsaafeen, B. H., Ali, B. R., & Elkord, E. (2025). Resistance mechanisms to immune checkpoint inhibitors: updated insights. Molecular Cancer. https://doi.org/10.1186/s12943-024-02212-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.